（央视财经《经济信息联播》）一支笔可以筛查帕金森病，一台眼底照相机可以提示高血压、脑梗风险。 这些医疗新科技将如何赋能我们的健康管理，马上去服贸会现场一探究竟。 总台央视记者 王舒畅：我手中这支笔，看起来普通，但内置很多传感器。只要拿起它，根据系统的指示音 做出举起、旋转和书写的动作，它就能辅助帕金森病的早期筛查和用药指导，产品明年将会上市。 参展商 任培：可以检测持笔的手细微抖动情况，握笔的时候手部的肌肉压力，我们可以从中提取出一些参 数，作为一个帕金森病早期筛查判断的数据。用户在家里可以把检测结果发送给他的主治大夫，不用去医 院。 AI眼底照相机，在服贸会最受老年观众的关注。只需在设备前拍摄一张眼底照片，就能生成关于高血压、 糖尿病、心梗、脑梗等方面的风险数值报告。 在服贸会现场有很多和中医有关的AI产品。这款导诊仪数字人叫"安安"。它能通过多轮问诊推荐科室，还 可以结合节气给出中医调理建议。它的智慧来自中医垂直大模型，目前这样的大模型已经在北京一些医院 落地。 当前，人工智能和大数据等前沿技术正在重塑医疗健康服务模式。未来，随着这些创新成果的推广应用， 医疗服务的质量有望进一步提升。 转载请注明央视财经 ...

Group 1 - The 2025 Service Trade Fair has entered its fourth day, featuring a public open day and showcasing the latest technologies and services in the healthcare sector under the theme "Smart Leading Future Health Life" [1] - The health and hygiene services area has become one of the most popular exhibition zones at this year's fair, highlighting advanced medical equipment such as microwave water knife laparoscopic surgical robots and single-port laparoscopic surgical robots [1] - A notable innovation is the panoramic reconstruction capsule robot, which navigates the digestive tract autonomously and can identify millimeter-level lesions using AI, potentially reducing the need for traditional gastrointestinal examinations [1] Group 2 - In the field of orthopedics, robotic assistance is now available for surgeries involving the spine and joints, enhancing precision and minimizing damage to surrounding tissues during procedures like ligament reconstruction [2] - The Beijing Red Cross Blood Center introduced a fully automated blood labeling and packaging robot system, which integrates machine vision recognition and robotic loading, generating over 8 million data entries annually for scientific decision-making [2]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Saily Medical Technology Group Co., Ltd., indicating a significant portion of shares has been pledged, but the company maintains that this will not affect its operations or control [2][5][6]. Group 1: Share Pledge Details - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, representing 10.30% of the total share capital, and has pledged 3,000,000 shares recently [2]. - After the recent pledge, Saihai Technology has a total of 17,000,000 pledged shares, which is 78.55% of its holdings and 8.09% of the total share capital [2]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares (4.58% of total share capital) and has pledged 5,300,000 shares, which is 55.01% of his holdings [2]. Group 2: Future Pledge and Financing - Within the next six months, 6,000,000 shares are set to mature, accounting for 19.18% of their holdings and 2.86% of total share capital, with a corresponding financing balance of 14.61 million yuan [5]. - In the next year, an additional 9,000,000 shares will mature, representing 28.78% of their holdings and 4.28% of total share capital, with a financing balance of 36 million yuan [5]. - The funds from the recent pledge are primarily intended to repay previous pledge financing debts, and the company asserts that it has the ability to repay these debts [5][6]. Group 3: Risk Management and Impact - The company states that the pledge will not impact its operations, main business, financing costs, or ongoing viability, and there is no risk of a change in actual control [6]. - The credit status of Saihai Technology and Mr. Wen Wei is reported to be good, with manageable pledge risks, and they are prepared to take measures if stock prices approach warning or liquidation levels [6].

据长木谷展台工作人员李佳音介绍，传统骨科手术室术中操作高度依赖外科医生的个人经验与肉眼判 断，其精准度和可预测性难以得到根本保障，而该产品填补了人工智能与机器人技术在骨科手术全流程 覆盖中的应用空白，配备AI全骨科智能规划系统，将传统手术规划时间从数周压缩至分钟级，仅需CT 影像，即可在5分钟生成个性化三维手术方案。 李佳音提到，术中，机器人的数智脑、数智眼、数智手可以三位一体地模拟非常有年资的骨科专家的经 验，来进行手术的精准执行，通过5G远程技术提供实时手术直播、跨国会诊和远程指导服务，实现无 地域、无限定场景的应用边界突破。 9月10日—14日，2025年中国国际服务贸易交易会（以下简称"服贸会"）在北京首钢园举行。位于首钢 园2号馆的健康卫生服务专题展以"智领未来，健康生活"为年度主题，记者在馆内看到，长木谷展台吸 引许多观众驻足，据了解，长木谷在本次服贸会期间首次出展了AI+手术机器人5G远程诊疗一体化平台 数智骨科手术室。 （文章来源：21世纪经济报道） ...

在服贸会，未来医疗触手可及！经络调理机器人、AI医生、手术机器人……你最想了解哪个项 目？ 制作：姜子涵 【纠错】 【责任编辑:焦鹏】 记者：王小玉 报道员：爱丽克斯 文字：高姗姗 刘菲 策划：刘洪 统筹：汤丹鹭 陈子夏 ...

9月12日，Medpark举办本月第一次投融资会。本次活动在延续以往投融资对接模式的基础上，还邀请了银行机构参与，为园内企业畅通多元化的融资通 道。 路演环节，博致医疗、欧畅医疗、天海佳合、科曼医疗、国科康成、艾普拜生物等六家Medpark园内企业依次登台，展示核心技术、商业模式及市场前 景，覆盖智能辅助生殖、手术机器人、生物材料、智能医疗影像、体外诊断等细分领域。 . 博致医疗 er P CALLER at 1 03 - 8 i 15 r 1 d 1 012 16 e 对接会现场交流活跃，企业与银行、投资机构代表围绕技术转化、市场拓展、融资需求等问题深入交流，沟通合作的可能性。 参会企业反馈，这种"股权+债权"相结合的融资对接方式能够同时满足企业短期运营和长期发展的资金需求，提高融资效率。接下来，Medpark将继续常态 化开展投融资对接活动，不断优化融资服务模式，为园内企业创新发展提供更加全面的金融支撑。 ...

Core Insights - The "Artificial Intelligence + Healthcare" seminar successfully took place during the 2025 China International Service Trade Fair, focusing on the integration of AI and healthcare, and announced significant achievements from the National AI Application Pilot Base in Beijing [1] Group 1: AI Applications in Healthcare - Over a hundred AI applications have been developed, covering 30 critical clinical scenarios, enhancing precision diagnosis and accelerating biopharmaceutical manufacturing [2] - The pilot base released four key achievements in precision diagnosis, including a secure medical data space service, a comprehensive medical data annotation service, and a unified AI application promotion service [2][3] Group 2: Collaboration and Partnerships - The seminar facilitated efficient connections between hospitals, research institutions, and pharmaceutical companies, resulting in several cooperation agreements [3] - The pilot base collaborated with three major hospitals to release significant results, including an ultrasound diagnostic model for cardiovascular diseases and an AI system for liver and gallbladder diagnostics [4] Group 3: Advancements in Biopharmaceutical Manufacturing - The pilot base introduced two major achievements aimed at improving pharmaceutical manufacturing efficiency, including a public service platform for drug development and a clinical trial management system [3]

Group 1 - The Pengbo (Hainan) Boron Neutron Hospital is set to open by the end of this year, with equipment testing currently underway [1] - The Hainan Free Trade Port is expected to enhance cooperation between Hainan and Hong Kong, with a promotional event scheduled in Hong Kong to attract investment [3] - Hainan has become the largest source of foreign investment from Hong Kong, with over 700 new Hong Kong-funded enterprises expected to be established in 2024, and direct investment exceeding 15 billion RMB [3] Group 2 - The Hainan Sigmas International Diving Center project is under construction and aims to open by June 2026, benefiting from policies like duty-free shopping and visa exemptions [4] - Economic cooperation between Hainan and Hong Kong is expanding across various sectors, including tourism, finance, and professional services [5] - The two regions are working on aligning regulations and institutional frameworks to facilitate economic collaboration, including optimizing mechanisms for arbitration recognition [5]

Core Viewpoint - Ant Group's CEO, Han Xinyi, emphasized that AI will not replace doctors in the foreseeable future but should serve as an assistant to enhance their capabilities [1] Group 1: AI in Healthcare - Ant Group is committed to using AI to support doctors, helping specialists expand their capabilities towards becoming general practitioners [1] - The company has established a medical health laboratory to explore AI-enabled multidisciplinary team (MDT) consultations [1] - Han stated that the only viable path for AI in healthcare is through human-machine collaboration [1] Group 2: Challenges in AI Medical Implementation - Han identified three core challenges in the implementation of AI in healthcare: high-quality data, suppressing hallucinations, and medical ethics [1] - High-quality data is fundamental, with costs for data labeling and training potentially exceeding hundreds of dollars per data point, requiring involvement from senior medical experts [1] - Suppressing hallucinations while maintaining model performance is a significant challenge, necessitating a balance between reducing errors and preserving service capability [1] - Ant Group has established a medical ethics advisory committee to explore regulations in this previously unaddressed area [1] Group 3: Market Focus and Strategy - Despite the healthcare market being valued at trillions, Ant Group is not in a rush to commercialize its AI healthcare solutions in the coming years [1] - The company aims to focus on accumulating professional data, suppressing model hallucinations, and building medical ethics frameworks [1] - Han believes that as long as the services are professional and trustworthy, users will naturally engage with them [1]

Core Viewpoint - The company primarily operates in the domestic market, providing AI-enabled medical solutions, with business lines including primary healthcare services, hospital services, patient services, and regional management platform solutions [5] Revenue and Profit Growth - Historical revenue and net profit growth rates show fluctuations, with a notable increase in revenue growth rate in 2023 compared to previous years [7][10] - The company's revenue for the first half of 2025 is composed of various segments: hospital solutions (0.529 billion), patient management services (1.043 billion), regional solutions (0.576 billion), and primary healthcare solutions (0.838 billion) [9] Financial Performance Metrics - In the first half of 2025, the average return on equity was -8.2%, an increase of 20.62 percentage points from the same period last year [14] - The company's total asset turnover ratio has shown a consistent trend, with a notable value of 0.44 times in 2025H1 [17] Asset and Liability Changes - As of the first half of 2025, significant changes in assets include a 7.7% increase in receivables, a 44.97% increase in long-term receivables, a 28.7% increase in inventory, and a 77.75% increase in contract assets [23] - On the liabilities side, long-term borrowings increased by 224.07%, and short-term borrowings increased by 68.61%, indicating a rise in the proportion of total assets [26] Liquidity Ratios - The company reported a current ratio of 1.60 and a quick ratio of 1.49 in the first half of 2025, indicating a stable liquidity position [29]